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Falls and gait impairment in Parkinson’s Disease (PD) is a leading cause of morbidity and
mortality, significantly impacting quality of life and contributing heavily to disability. Thus
far axial symptoms, such as postural instability and gait freezing, have been refractory to
current treatment approaches and remain a critical unmet need.There has been increased
excitement surrounding the surgical targeting of the pedunculopontine nucleus (PPN) for
addressing axial symptoms in PD. The PPN and cuneate nucleus comprise the mesen-
cephalic locomotor region, and electrophysiologic studies in animal models and human
imaging studies have revealed a key role for the PPN in gait and postural control, underscor-
ing a potential role for DBS surgery. Previous limited studies of PPN deep brain stimulation
(DBS) in treating gait symptoms have had mixed clinical outcomes, likely reflect targeting
variability and the inherent challenges of targeting a small brainstem structure that is both
anatomically and neurochemically heterogeneous. Diffusion tractography shows promise
for more accurate targeting and standardization of results. Due to the limited experience
with PPN DBS, several unresolved questions remain about targeting and programing. At
present, it is unclear if there is incremental benefit with bilateral versus unilateral targeting
of PPN or whether PPN targeting should be performed as an adjunct to one of the more
traditional targets.The PPN also modulates non-motor functions including REM sleep, cog-
nition, mood, attention, arousal, and these observations will require long-term monitoring
to fully characterize potential side effects and benefits. Surgical targeting of the PPN is
feasible and shows promise for addressing axial symptoms in PD but may require further
refinements in targeting, improved imaging, and better lead design to fully realize benefits.
This review summarizes the current knowledge of PPN as a DBS target and areas that
need to be addressed to advance the field.
Keywords: pedunculopontine nucleus, deep brain stimulation, Parkinson’s disease, microelectrode recording,
postural instability, gait freezing, diffusion tractography
CURRENT STATUS OF PPN DBS
Major morbidity and mortality in Parkinson’s disease (PD) have
been closely linked to problems arising from falling. Indeed, the
resultant sequelae from hip fracture and aspiration pneumo-
nia are both appreciated as leading causes of PD related death
(1). Long-term pharmacological therapy has failed in adequately
treating axial motor symptoms of PD including fall related mor-
bidity, ambulatory difficulties, balance problems, freezing, and also
swallowing dysfunction. Deep brain stimulation (DBS) addresses
primarily PD motor symptoms with the most commonly uti-
lized stimulation targets being the subthalamic nucleus (STN)
and the globus pallidus internus (GPi) (2–5). Stimulation of these
two specific targets, while producing striking improvements in
tremor, bradykinesia, rigidity, and levodopa-induced dyskinesia
(6–8) have unfortunately fallen short in alleviating important
disease related PD morbidities, especially levodopa unresponsive
gait impairment, freezing, falling, and swallowing issues.
Thus an unmet but pressing need exists to develop novel ther-
apeutic strategies to treat disabling levodopa and DBS resistant
axial disturbances in PD. Because the pedunculopontine nucleus
(PPN) is an integral component of the mesencephalic locomotor
system, and because it coexists within a rich brainstem network
thought to have a modulatory role in many motor and non-motor
PD features, there has been recent enthusiasm for this novel tar-
get. Indeed, early and promising data suggested that the PPN could
be a viable DBS target for treating axial symptoms. Several small
non-randomized, non-controlled studies examining short-term
outcomes have been performed (see Table 1).
The excitement in the field about a novel DBS target (PPN)
potentially capable of addressing medication resistant axial motor
symptoms (freezing, falling, and swallowing) has been tempered
by mixed clinical outcomes that have ranged from excellent to
uncertain. Almost all of the studies have been open label and have
not had rigidly defined inclusion criteria. Also, there has not been
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Table 1 | Studies on PD patients implanted with PPN DBS.
Study Subjects Target Inclusion Study design Effect on FOG/PI Falls UPDRSIII Adverse events Comments
Plaha and
Gill (9)
2 Bilateral PPNPPN FOG, PI, falls in
both the ON and
OFF states
Open label + (2/2) ON and
OFF medication
+ (2/2) ON and
OFF medication
+ (2/2) In both
ON and OFF
medication states
Worsened gait
and motor at
certain
frequencies
Patients had contrasting
profiles at higher frequencies,
follow up at 16 and 42 days
Strafella
et al. (10)
1 Unilateral PPN Advanced PD of
at least 5 years
duration, >30%
benefit in ON
state, FOG, PI
Open label Benefit on gait
subscore of
UPDRSIII
NA + (1/1) OFF
medication
benefit of 19% on
UPDRSIII
NA PET study showing increased
rCBF in subcortical areas
bilaterally, thalamus
Brusa et al.
(11)
1 Unilateral PPN PSP-P w/FOG, PI Open label 0 0 + (1/1) UPDRSIII
22 to –18 at
3 months
Intensity
dependent
paresthesias
Slight improvement in
subjective gait ignition failure
Moro et al.
(12)
6 Unilateral PPN Age<70,
absence of
dementia, severe
off PI and FOG
Double blind 0 + (in falls at 3 and
12 months, falling
score 70%
improved
0 (no difference in
ON and OFF stim
in ON and OFF
med states at 3
and 12 months)
Intensity and
frequency
dependent
paresthesias,
oscillopsia
Medication responsive on
gait, posture, freezing
subscores of UPDRS
Ostrem
et al. (13)
1 Bilateral PPN PPFG Open label + (FOG
questionnaire)
0 0 None Mild improvement on FOG
questionnaire not sustained
at 12 months
Thevathasan
et al. (14)
5 Bilateral PPN Severe FOG, PI,
falls persisting in
ON state
Open label + (5/5 patients by
questionnaire at
3 months and
2 years)
+ (5/5 at
6 months and 4/5
at 2 years)
0 Oscillopsia,
frequency
dependent
worsening of
motor and gait
Followed over 2 years.
Wilcox et al.
(15)
1 Bilateral PPN Primary
progressive
freezing of gait
Open label + (questionnaire
and gait testing)
+ (questionnaire) + (1/1) None reported Followed to 14 months
Aviles-
Olmos
et al. (16)
1 Unilateral PPN Gait and balance
impairment in on
state
Open label + 0 0 Urinary
incontinence
Gait analysis showed
improvement in freezing and
velocity but not sufficient to
improve UPDRS subscores
(Continued)
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Table 1 | Continued
Study Subjects Target Inclusion Study design Effect on FOG/PI Falls UPDRSIII Adverse events Comments
Thevathasan
et al. (17)
7 5 bilateral PPN, 2
unilateral PPN
FOG, PI, falls
persisting in the
on state
+ (6/6 patients at
follow up
2—13 months by
questionnaire,
less robust in
unilateral
patients)
+ NA Not reported 1 patient published in
previous study, gait freezing
improved OFF stim for up to
6 weeks
Stefani
et al. (18)
6 Bilateral
STN+PPN
UPDRSIII>70,
disabling axial
symptoms, 3 of 6
had ON
medication FOG
Open label PPN had much
better benefit on
posture and gait
items compared
to STN.
NA + (6/6) ON and
OFF PPN only ON
mean 32%
improvement in
UPDRSIII
compared to 54%
improvement
with STN ON.
paresthesias Slight decline in efficacy of
PPN after 6 months, trend
toward increased benefit on
UPDRS III with both STN and
PPN ON
Androulidakis
et al. (19)
6 2 bilateral
STN+PPN, 2
unilateral
STN+PPN, 1
unilateral
GPi+PPN, 1
unilateral PPN
Severe PD, FOG Open label NA NA + (6/6) in ON
medication state
Not reported Intraoperative recording.
Clinical gait measures not
reported. Unilateral PPN case
previously reported in (18).
Mazzone
et al. (20)
14 8 bilateral, 6
unilateral 5
bilateral
PPN+STN, 1
bilateral PPN with
1 lead explanted,
5 unilateral PPN,
1 unilateral
PPN+GPi, 1
bilateral
GPi+CM-PF
12 PD and 2 PSP Open label + (mean
improvement on
posture and gait
subscores of
UPDRS)
NA + Transient
paresthesias
Follow up at 15 day test
period for acute and
1–24 months for chronic
effects of DBS.
(Continued)
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Table 1 | Continued
Study Subjects Target Inclusion Study design Effect on FOG/PI Falls UPDRSIII Adverse events Comments
Thevathasan
et al. (21)
11 8 bilateral PPN, 2
bilateral PPN+ZI,
1 unilateral
PPN+bilateral ZI
FOG, PI, falls
persisting in ON
state
Open label + + (10/11) 0 None reported Gait, posture, balance
assessed by UPDRS
subscores 27–30, follow up at
3–38 months
Ferraye
et al. (22)
6 Bilateral
PPN+STN
Severe gait and
freezing despite
STN
Double blind 0 (composite gait
score, FOG
questionnaire,
duration of
freezing)
0 0 Seizure in 1 pt,
frequency
dependent
oscillopsia,
paresthesias,
limb myoclonus
Objective freezing improved
in 2 patients in levodopa ON.
Outcomes at baseline and 1
year follow up.
Mazzone
et al. (23)
23 6 bilateral
STN+PPN, 3
bilateral
GPi+unilateral
PPN, 1 unilateral
GPi+unilateral
PPN, 13 unilateral
PPN
22 PD and 1 PSP Open label + NA + (23/23) Transient
paresthesias
reported in earlier
series
Includes patients from
Mazzone et al. (20, 24). Last
17 patients had unilateral PPN
showing similar benefits to
traditional targets of STN and
GPi.
Khan et al.
(25)
7 Bilateral PPN+ZI FOG, PI, falls in
both off and on
Open label + (improvement
in axial subscores
with both PPN
and ZI on)
NA + (both OFF and
ON medication
states, ZI had
greater benefit
than PPN)
Self limited
akinesia postop in
2 patients
No significant diff between ZI
ON versus both PPN and ZI
ON for UPDRSIII, follow up at
baseline and 12 months, trend
toward improvement with
both, sig with axial subscore
Franzini
et al. (26)
2 Unilateral 1
STN+PPN, 1PPN
Falls and gait
difficulty, one
patient had
akinesia due to
neuroleptic abuse
Open label NA NA + (UPDRSIII 29 to
15 in one patient,
gait improved in
other)
Not reported Gait and falls improved by
report but not quantified.
PD, Parkinson disease; PPN, pedunculopontine nucleus; STN, subthalamic nucleus; GPi, globus pallidus, internal segment; ZI, Zona Incerta; FOG, freezing of gait; PI, postural instability; UPDRS, United Parkinson
Disease Rating Scale; rCBF, regional cerebral blood flow; +, improvement; 0, no improvement, NA, not available.
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Morita et al. Future directions for PPN DBS
a standardized outcome measures battery of both subjective and
objective measure of freezing of gait (FOG), postural instability,
and falls. Most studies have used either the gait and posture sub-
scores of the UPDRSIII or FOG and gait and falls questionnaires.
PPN DBS studies have been summarized in Table 1.
The Plaha et al. study showed impressive improvements in
UPDRS III motor scores as well as improvements with falls and
FOG in both the ON and OFF medication states in two patients
with bilateral STN DBS plus bilateral PPN DBS, however, the study
was open label, and there was no clearly defined outcome measures
for FOG, falls, and postural instability. This report was followed
by Stefani and colleagues’ study who also evaluated bilateral STN
and bilateral PPN DBS as a combination treatment. Stefani’s team
performed a six patient open label study without rigid inclusion
criteria, and like Plaha they reported impressive UPDRS III motor
changes in both the ON med and OFF med states. PPN DBS
improved gait and postural stability more than STN DBS, but
did not improve limb function as much as STN DBS. However,
the combination of PPN and STN DBS improved both axial and
limb function more than either target alone. In a larger series
by Mazzone et al. in a series of 14 patients that consisted of a
combination of unilateral and bilateral PPN targeting, some with
concurrent or previous targeting of STN, GPi, there were mean
improvements of UPDRS III and posture and gait subscores of
UPDRS III (20). The results of these open label studies have been
mitigated to some extent by Ferraye’s recent report of a double
blind trial of bilateral STN and bilateral PPN DBS in six patients.
Ferraye’s group concluded that freezing and falling improved in
5/6 patients, but the UPDRS III gait items did not improve. In this
study, medication status (ON versus OFF freezing) and falling were
not detailed in the inclusion criteria. Moro et al. in 2010 reported
that in six patients with unilateral PPN DBS (no previous STN
surgery), the UPDRS motor scores did not improve with a dou-
ble blind evaluation, however, falls on the UPDRS II scale were
decreased (12). The Moro study did not use bilateral implants,
and only required participants to exhibit falling in the off med-
ication state, and not in the on medication state. Thevathasan and
coworkers have performed a series of studies looking at patients
with bilateral PPN DBS without implantation of other traditional
targets. The patients in these studies all had FOG, postural insta-
bility, and falls persisting in the ON medication state as inclusion
criteria and all had improvements in FOG, postural instability,
and falls using questionnaire as an outcome measure, however,
these patients did not have improvements in non-axial associ-
ated UPDRS measures (14). Improvements in FOG, PI, and falls
seemed to be less robust in patients implanted in PPN unilaterally
though the data were limited (17). The approach of the Mazzone
and coworkers group has evolved with technical improvements
in their procedure and increased experience, now with at least
23 patients with PPN implantations (23). Initially, their patients
were implanted with both PPN and STN DBS simultaneously in
one hemisphere then 10–15 days later in the contralateral PPN
and STN. With refinements in their techniques, they have since
reported switching to a preferred strategy of unilateral PPN tar-
geting with consideration of PPN as a primary target (23). In
this study, there were no significant differences in the UPDRS
subscores 27–30 and OFF DBS and ON DBS when comparing
patients with combined implantations and those with unilaterally
implanted PPN.
Several critical issues must be clarified to truly determine the
viability of PPN DBS for the treatment of PD related axial symp-
toms. First, examination of the efficacy of PPN DBS should be
performed in a carefully selected drug-resistant population, and
it should be performed with and without existing STN or GPi
DBS systems in order to sort out its true therapeutic effects. Such
an examination will clarify the independent role and potential
additive benefits of PPN DBS on drug-resistant axial PD symp-
toms. Furthermore, this type of careful examination will aid in
determining the patient characteristics that may predict a better
outcome.
Additionally, optimal localization of lead placement within the
PPN is not trivial. In fact, placement of DBS leads in the brainstem
PPN region has produced more variability in targeting than has
been previously observed for other DBS procedures. This feature,
until resolved, possibly limits the PPN as a viable surgical target.
More rigorous and advanced targeting and localization procedures
are needed with careful follow-up imaging and likely tractography.
Ultimately, this may require advancements in lead design to create
PPN specific leads.
Historically, the initial studies of GPi and STN DBS dra-
matically underreported the incidence and nature of motor and
non-motor adverse effects. There has also been significant concern
about potential adverse events resulting from PPN DBS as the PPN
is located in a region close to many important brainstem centers.
Because there have been so few reports of PPN DBS, adverse event
data have been sparse and mainly limited to oscillopsia, paresthe-
sias, and urinary incontinence (12, 16, 18, 22, 27), which may vary
depending on target location. Some of the motor side effects can
be predicted based on the anatomic relationship of the PPN, how-
ever, the PPN also plays a role in modulating several non-motor
systems with less predictable effects. Careful and critical exami-
nation and reporting of adverse events are needed to clarify the
safety of PPN DBS and to determine which patient characteristics
may place a patient at greatest risk.
Finally, the precise nature of axial motor dysfunction and inci-
dence of falling pre- and post-PPN DBS need to be quantified.
These objective and sensitive analyses will require specific and
well-selected outcome measures. From these, clinical trials will be
in a better position to sort out the features that are captured by
PPN stimulation, and what patient characteristics or clinical out-
come measures may predict a better outcome from surgery. In this
paper, we will address what is known about PPN DBS, and we will
make recommendations to help the field move forward.
PPN ANATOMY, PHYSIOLOGY, AND IMAGING GUIDANCE
FOR DBS
In advanced PD, many deficits including problems with ambula-
tion, postural instability, FOG, falls, and swallowing disturbances
are levodopa refractory, and thus not entirely explained by dys-
function of nigrostriatal dopaminergic pathways (28–32). There-
fore, a likely explanation is that in parallel to the nigro-striatal-
pallido-thalamo-cortical neuronal circuits mediating voluntary
movements, there exist reciprocal pathways between the basal gan-
glia and brain stem/spinal cord nuclei that may modulate at least
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some of these functions [reviewed in Ref. (33)]. Recent evidence
suggests that the PPN plays an integral role in deficits seen in
PD, and since the control of locomotion and posture seem to
depend more on the brainstem than on cortical control, atten-
tion has turned to this brainstem based nucleus, in particular the
mesencephalic locomotor region (MLR) (34–36).
The MLR consists of the PPN and the cuneate nucleus
and is both anatomically and neurochemically heterogeneous
(Figure 1) consisting of cholinergic, non-cholinergic, and mixed
neurons (37).
In normal humans, faster imagined gait results in marked
MLR activation during fMRI further implicating this region in
locomotion (38).
Much of our understanding of the role of PPN in locomotion
has been extrapolated from studies performed in non-human pri-
mates and rats. The rostral to caudal corticolimbic-ventral striatal-
ventral pallidal-PPN-pontomedullary reticular nuclei-spinal cord
pathway likely mediates various phases of locomotion including
initiation, acceleration–deceleration, and termination of locomo-
tion (31, 37, 39–41). The rostral to caudal locomotor pathway is
modulated by parallel connections from the deep cerebellar and
basal ganglia systems and integrated at the PPN, with prominent
projections from the STN, GPi, and SN. Ventral pallidal outflow
tracts to the PPN mediate spontaneous locomotor activity as evi-
denced by pharmacological manipulations performed in rat stud-
ies including (1) carbachol injection into unilateral PPN which led
to reduced spontaneous locomotor activity and renormalization of
enhanced locomotor activities seen with amphetamine injection
into the nucleus accumbens and (2) procaine injection into the
PPN suppressed the increased locomotor activity normally seen
with hippocampal stimulation (42–44). MPTP intoxication in old,
but not young monkeys induced balance and posture abnormal-
ities; this was a significant finding because cholinergic neuronal
loss in the PPN is present only in the older monkeys. Further-
more, direct bilateral PPN selective cholinergic neuron lesioning
in monkeys (without MPTP treatment) causes axial rigidity and
abnormalities of posture and gait without modifying overall global
motor activity (38). Apomorphine administration improves the
postural and gait abnormalities in monkeys previously treated
with MPTP, but not in those receiving direct PPN cholinergic
lesions (38, 45). The substantia nigra seems to play an important
role in the initiation of locomotion and be potentially modulated
by the PPN. The PPN likely modulates locomotor rhythmicity. Up
to 70% of the neurons ventrally or dorsally adjacent to the PPN
display burst firing which is correlated with cyclic frequencies of
locomotion (46). By contrast, the majority of neurons in the PPN
show tonic firing and are active during transitions of locomotion,
activating or inactivating the rhythmic bursting neurons and firing
transiently to initiate or terminate locomotion (46). Extrapolating
from these animal studies, PPN circuitry may be involved in axial
motor dysfunction (freezing/falling/swallowing) in the human.
Pathological and functional changes of the PPN have been
observed in both animal models of PD and in patients with PD. A
pathological study on eight patients with idiopathic PD revealed
a 40% loss of large neurons within the PPN (39). Additionally,
the severity of PPN neuronal loss was positively correlated with
the severity of PD symptoms, and correlated to neuronal loss in
FIGURE 1 | Anatomical connections of the PPN. SNr, substantia nigra;
SNc, substantia nigra pars compacta; STN, subthalamic nucleus; GPi,
globus pallidus internal segment; PPNc, pedunculopontine nucleus pars
compacta; PPNd, pedunculopontine nucleus pars dissipatus; ChAT, choline
acetyltransferase. Image from the American Academy of Neurology image
library.
the substantia nigra. Cholinergic neuron loss in the PPN was
also greater in patients with PD who fell compared to similar
PD patients who did not fall (39, 47). These observations add to
our understanding of levodopa-resistant posture and gait deficits.
Furthermore, the identification of cholinergic neurons specifically
involved with control of gait and posture could improve targeting
for DBS in this area. The close proximity of cholinergic and non-
cholinergic regions within the PPN may result in current spread
from one region to the other, therefore careful studies correlating
exact electrode location and clinical effects are needed.
In PD, the increased inhibitory (GABAergic) activity from the
GPi is thought to inhibit the PPN, and this has been shown in
non-human primate models of PD revealing diminished PPN fir-
ing rates (48, 49). Further, stimulation or disinhibition of PPN via
GABA antagonists has been shown to alleviate akinesia. However,
these findings have not been universal and several groups have
suggested that there is PPN overactivity in PD and that DBS ben-
efits may be due to dampening PPN activity (23). In summary,
PPN activity in PD is not clearly understood.
There is an ongoing debate as to where the PPN is located,
and where groups have actually targeted the nucleus (e.g., PPN
versus peri-peduncular)(50, 51). The mixed clinical outcomes in
PPN DBS studies may therefore be a function of targeting variabil-
ity. From a logistical standpoint, typical DBS fields of stimulation
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range between 2 and 3 mm and targeting errors range up to
3 mm. Computational modeling has shown that even small sur-
gical targeting errors of 1 mm can lead to large decrements in
activation of PPN (52). In addition, the PPN is anatomically
and neurochemically heterogenous with subdivisions containing
cholinergic, GABAergic, and glutamatergic neurons. With current
stimulation parameters, current spread will necessarily affect mul-
tiple cell types. Due to these technical challenges, satisfactory PPN
targeting may require further refinements in lead design. Some
of these refinements may include PPN specific leads with small
diameters, and with an increased number of electrical contacts and
with a reduced intercontact distance, or alternatively with current
steering technologies.
Since microelectrode recording and plain MRI imaging can-
not clearly delineate PPN borders, there has been a movement
to exploit diffusion tension imaging (DTI) in order to identify
tracts originating and terminating in the PPN. Indirect MRI based
targeting can be used to define an approximate region for PPN
DBS. One common targeting method has utilized the mean coor-
dinates for the caudal and rostral edges of the PPN provided by
Zrinzo et al. (see Figure 2). Direct MRI based targeting (i.e., T1
and FGATIR imaging can be used to reveal large contrast differ-
ences between gray and white matter) and to directly delineate
a voxel corresponding to the midpoint of PPN. The midpoint
voxel can be expanded in each direction creating a large cube
(~6× 6× 6 mm3) to contain the general boundaries of PPN. Since
the extent of the PPN is not well defined from anatomic imaging
alone, diffusion tractography can be used to identify a more spe-
cific tract of interest for stimulation. Tractography from the PPN
cube seed region can be used to reveal numerous subcortical con-
nections including the thalamus, STN, SNr, and pallidum (53).
Cortical connections can include the somatosensory cortex (S1),
primary motor cortex (M1), supplementary motor areas, and pre-
motor cortex (see Figure 2). Final refinement of the target can
then be achieved by limiting tractography to the particular func-
tional connection of interest. In order to identify the tract for lead
placement, only fibers from the previously mentioned PPN cube
(which pass through ventrolateral thalamus) that terminate in the
motor cortex should be traced. Lead placement can be guided by
selecting a trajectory that follows the tract from the region con-
taining PPN to the lower trunk (e.g., legs) representation of motor
cortex (specifically M1). Microelectrode recording passes can be
also be used to differentiate PPN from adjacent structures with
the data used in physiological research and potentially for guiding
chronic stimulation settings. Though it is not yet feasible to clearly
delineate the boundaries of PPN using microelectrode recordings
and no unique signature activity has been identified, neuronal
activity in the PPN differs by statistical measures of spontaneous
activity from neighboring structures. Microelectrode studies of
PPN in human patients have shown that the PPN has different
spontaneous activity with a higher proportion of neurons with
bursting discharge when compared with regions dorsal or ventral
to PPN (19, 54, 55). In these studies, local field potentials recorded
from the PPN showed greater power in the beta frequency range,
potentially aiding in localization. Wide duration action poten-
tials were thought to correspond with cholinergic neurons in PPN
(54, 55). A combined approach utilizing tractography and micro-
electrode recording is one possible way investigators can try to
FIGURE 2 | Probabilistic diffusion tractography for surgical targeting and planning of a PPN DBS implantation guided by an fast gray matter
acquisitionT1 inversion recovery (FGATIR) MRI scan.
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narrow the target region for PPN DBS, but more research will be
needed.
Nevertheless, the Toronto group’s surgical approach [using
MRI-guided targeting and microelectrode recording (12)] has
proven to be reasonably effective in targeting the PPN. Indeed,
pathological analysis in two patients with progressive supranuclear
palsy (PSP) who had undergone unilateral PPN DBS surgery has
confirmed the position of the electrodes in the PPN region (56).
Probabilistic diffusion tractography maps in Figure 2 were
created using in-house created software in conjunction with the
FMRIB Software Library (FSL). FSL was used to determine the
parameters for a two-fiber diffusion model at each voxel. This
fiber model was then used with the FSL software to perform
probabilistic tractography. This type of tractography allowed for
a representation of the relative cross-sectional probability of a
streamline passing through a voxel. A high contrast MRI scan,
FGATIR (57), was used to help delineate the anatomic region
around the PPN. A large region of interest around the region of
the PPN that fully encompasses the PPN was used as a seed for
tractography. If no mask is used to limit the tractography results,
probabilistic tractography results may not be specific enough to be
useful for surgical targeting (as shown in the top row of Figure 2).
The top row images are (from left to right) a sagittal view of tracts
from a large seed region including the PPN with fibers traveling
from the PPN to various cortical and subcortical areas, an axial
view of tracts in the PPN, and sagittal and axial views adapted
with permission from Zrinzo et al. (58, 59) that show the location
of the PPN identified from anatomy (using T1 and proton den-
sity weighted MRI). The top row highlights the older technique
for DTI of the region, where the fiber pathway would be difficult
to target because of specificity issues. The upper right image (top
row) is the figure from Zrinzo et al. [figures adapted from Zrinzo
et al. (59), permission for use of figures was obtained] (58, 59)
and what has been shown red is the PPN, yellow is the lemniscal
system, green is the superior cerebellar peduncles, and blue is the
central tegmental tract.
A specific waypoint mask can be used to limit the results of
probabilistic diffusion tractography to only include tracts that pass
through a particular region of interest. For Figure 2 middle and
bottom rows, a region of interest mask was created around the
M1 primary motor cortex. We used this mask to limit the trac-
tography results to only include the region of the PPN that has
fiber connections to the primary motor cortex (M1). Middle row
images (from left to right) show a medial sagittal slice of tracts
from M1 to the region of the PPN, a lateral sagittal slice of tracts
from M1 to the region of PPN (the tracts are going through VL
(motor) thalamus, specifically Vim, Vop, and Voa), and an axial
view of the tract from M1 to PPN. The right image of the second
row shows correspondence with the location of PPN (top right
panel) given by Zrinzo et al. (58, 59). The third bottom row shows
more caudal cuts of PPN into the pons. The two bottom rows
reveal the potential specificity of the technique for targeting with
the DBS lead.
The refined PPN tract matches the same area that is [the red
dot (PPN)] shown in the Zrinzo’s work, and it is felt to be likely
the PPN proper. The top row images show the current and less
specific methods to localize PPN and its tracts. The tracts likely
include areas that are not PPN. The bottom rows are tracts from
M1 to the region including PPN based on the University of Florida
methodology. The idea of locating PPN should focus on sub-
cortical connections and also those connections to motor cortex.
Theoretically, a DBS lead (3389, 4 1.5 mm contacts with 1.5 mm
spacing) can be placed into the tract to give the programmer in the
clinic many options including the center of the PPN region itself
(deepest lead), and three contacts along the PPN tract headed
toward cortical and subcortical regions of interest, specifically the
thalamus and ultimately the M1 region. However, specific leads
designed for PPN DBS may be needed to achieve more consistent
results. It is unknown whether this type of DTI imaging approach
will ultimately improve targeting and outcomes; however, because
of the uncertainty of the location of the PPN target, refinement
techniques such as this will need to be further developed.
UNILATERAL VERSUS BILATERAL PPN DBS
Although the initial reports of PPN surgery in humans involved
patients with advanced PD who had previously or concurrently
undergone bilateral STN DBS, most previous clinical data were
derived from unilateral PPN lesions or stimulation in normal or
Parkinsonian animals. In a Parkinsonian monkey, unilateral PPN
low frequency stimulation (LFS) improved generalized akinesia,
whereas in Parkinsonian rats unilateral LFS of the PPN improved
postural instability and contralateral limb use. These animal data
suggest that unilateral PPN stimulation may thus have bilateral
effects. To support these findings it has been shown in animals
that the PPN has bilateral connections through a complex basal
ganglia network (41). Moreover, bilateral PPN connections have
been recently visualized in humans with PET studies (10).
The most recent clinical studies reporting effects of PPN DBS
in PD patients have involved bilateral implantation with only few
exceptions (10, 12, 16, 19, 21, 23, 26, 60, 61). Bilateral surgery has
also been performed in a patient with primary progressive freez-
ing gait disorder (13, 15). However, when comparing the French
and Canadian studies, both with double blind measured changes
in gait parameters (freezing) and balance as primary outcomes,
unilateral and bilateral PPN stimulation achieved similar results
in improving freezing at 1 year follow-up (12, 22). The group
of Mazzone and coworkers has reported improvements in their
technique with findings of similar benefit with unilateral PPN
implantation (23).
Data from long-term observations are lacking, and the Toronto
group has observed a progressive loss of the initial axial improve-
ment (balance and freezing) after 3 years in two patients who had
unilateral PPN DBS surgery. Interestingly, a new DBS surgery in
the contralateral PPN restored the initial benefit in one patient and
partially restored it in the other patient (personal communication
Moro).
These findings raise several interesting questions that should
be addressed in future studies:
Is it necessary to perform bilateral PPN DBS if a unilateral
approach is safer and also potentially effective?
Should PPN DBS surgery be staged bilaterally or performed
bilaterally and simultaneously in the same operating room
sitting?
Frontiers in Neurology | Movement Disorders December 2014 | Volume 5 | Article 243 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Morita et al. Future directions for PPN DBS
How much greater benefit, if any, is generally achieved with bilat-
eral PPN DBS compared to unilateral PPN DBS? Furthermore, it
is unknown whether there is lateralization of PPN function as has
been described in limited studies of STN for PD (62, 63). fMRI
studies of fast imagined walking in right handed normal individ-
uals selectively activated the left PPN region suggesting a poten-
tial dominance of the left side for locomotor function. Additional
activation has also been observed in the left SMA which is con-
nected to the left PPN, and may thus be part of the dominant right
leg representation. Comparing the effects of unilateral and bilat-
eral stimulation in patients who have already undergone bilateral
PPN electrode implantation along the lines of the Thevathasan
et al. studies could potentially provide answers to these questions.
POTENTIAL APPROACHES TO PPN DBS PROGRAMING
Much of the data regarding DBS programing of the PPN have been
extrapolated from studies performed in non-human primates and
rats. When comparing the neuronal firing of the PPN with other
basal ganglia nuclei (STN and GPi) in the Parkinsonian state, the
PPN has revealed a much lower firing rate. In the normal rat, the
PPN firing rate has been reported to fire at approximately 10 Hz,
in comparison to the increased cell firing, irregularity and bursty
pattern (18–20 Hz) observed in the Parkinsonian rat (64). PPN
firing rates in PD patients have been described at approximately
14–25 Hz (19, 24, 54, 55).
Additionally, PPN stimulation with low and high frequency has
shown different, and sometimes opposite effects when compared
to STN stimulation. In normal non-human primates, PPN stim-
ulation with low frequency (<30 Hz) induced tremor, whereas
stimulation with high frequency (>100 Hz) decreased locomo-
tor activity (65). In Parkinsonian non-human primates, PPN LFS
at 5 Hz increased motor activity (54, 66–68) whereas PPN HFS
resulted in akinesia (54, 66–68).
These non-human data have helped to direct the programing
of PPN DBS in PD patients. Intraoperative data initially revealed
improvement with LFS rather than HFS (24) but these results have
not been consistently found during post-operative programing
(9). Specifically, frequencies between 80 and 130 Hz have produced
variable outcomes between groups ranging from no benefit (12,
24) to worsening (9) or to improvement (9) of gait scores.
Most groups have utilized PPN DBS at 25 Hz settings bilaterally
(13, 18, 22, 69). However, no systematic investigation of low and
high frequency stimulation was clearly performed in these stud-
ies. The Toronto group has systematically investigated different
frequencies of stimulation (5, 20, 50, 70, and 130 Hz) in the PD
patient with unilateral stimulation, and observed the most benefi-
cial effects occurring around 50–70 Hz (12). The other parameters
of stimulation (pulse width and voltage) did not seem to differ
across studies. The reasons for these different frequency effects
remain unclear.
Prior STN DBS may affect PPN function and the response to
PPN DBS. Vitek and coworkers have recently observed that in
primates with MPTP induced Parkinsonism treated with high fre-
quency STN DBS there was a marked reduction in PPN activity
(70). By contrast, in the initial human studies STN stimulation
had only mild effects on PPN firing (24). The effects of STN
stimulation on PPN activity have not fully been characterized,
however, in patients with high frequency STN DBS that initially
improved and subsequently developed a gait disorder, switching
to low frequency (60 Hz) STN DBS may improve gait presumably
through relieving the inhibitory input of the STN on the PPN.
Indeed, Khan et al. reported that high frequency Zi stimulation
worsened postural stability when combined with low frequency
PPN DBS, and that the benefit was only achieved by reducing STN
stimulation frequency to 60 Hz (25). Data from several groups
have suggested that 60 Hz STN stimulation was similarly effec-
tive for ameliorating Parkinsonism, suggesting this strategy will
not negatively impact symptoms primarily captured by STN DBS
with perhaps the exception of tremor (71). Differing locations for
stimulation in the PPN region and differing patient phenotypes
might also contribute to the wide variability in stimulation para-
meters reported. Further studies correlating electrode position
and effective stimulation parameters in patients with and with-
out simultaneous STN DBS will be critical to help guide future
DBS programing.
In the absence of more extensive studies, a rational approach
to PPN DBS programing would include the use of a systematic
manipulation of stimulation frequencies, starting with LFS and
then progressively increasing stimulation up to 70–80 Hz if needed
and perhaps higher in select cases.
There are both predictable and unpredictable side effects asso-
ciated with DBS programing. The predictable side effects are based
simply on the anatomical relationships of neighboring structures
and have been well delineated by Lozano and colleagues (72). Less
predictable are the non-motor side effects of PPN DBS, due to our
limited understanding of the PPN in modulating these functions.
Deep brain stimulation for GPi and STN has the advantage
that many of the symptomatic benefits can be approximated with
macrostimulation in the OR. Bradykinesia, tremor, and rigidity
are amenable to in person testing. Surrogate testing for postural
instability or gait freezing are not currently amenable to macros-
timulation in the OR. Imagined gait has been used in protocols to
study the role of PPN in gait, but would require validation in clin-
ical studies (38, 73). Identification of clinical outcome measures
that can predict response to PPN DBS will be critical to move the
field forward.
THE IMPORTANCE OF NON-MOTOR FUNCTIONS OF THE PPN
REGION
Non-motor symptoms (NMS) of PD in many cases overshadow
the motor symptoms (74, 75) and severely affect the quality of life
for PD patients. NMS include autonomic dysfunction (gastroin-
testinal disorders, orthostatic hypotension, erectile dysfunction,
sweating and urinary abnormalities), sleep disorders (restless legs
syndrome, periodic limb movements of sleep, excessive daytime
sleepiness, insomnia, REM sleep behavior disorder, and obstruc-
tive sleep apnea), cognitive dysfunction, mood disorders, and
fatigue.
The non-motor effects of PPN DBS are less well characterized
when compared to the traditional targets of the STN or GPi. This is
not unexpected, since the non-motor functions of the PPN region
are not well understood in humans and additionally NMS in PD
have been historically much less emphasized. Finally, PPN DBS
has been performed mainly to target motor and not non-motor
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disability. As PPN DBS moves forward, careful examination and
tracking of changes in non-motor features will be important.
The PPN is thought to be involved in sleep, cognition, and in
processing sensory and behavioral information (35). Deep brain
areas involved in sleep have been studied mainly in animals. In cats,
some cholinergic neurons in the PPN region have shown increased
firing rates during rapid eye movement (REM) sleep (REM “on”
neurons) (76). The Toronto group has also demonstrated that the
presence of ponto-geniculo-occipital waves during REM sleep in
humans can be recorded from an externalized PPN electrode (77).
The effects of bilateral PPN DBS on REM sleep were previously
reported in one PD patient who underwent bilateral STN and PPN
DBS surgery (78). Bilateral PPN DBS at low frequency (25 Hz) was
associated with increased REM sleep (around 13%). In the same
patient, bilateral STN DBS improved sleep efficiency by 80%, but
did not have a major impact on REM sleep duration. The authors
suggested that LFS of the PPN might modify the functional activ-
ity of cholinergic neurons, activating muscarinic receptors, and
rebalancing REM sleep physiology through associated thalamic
projections. Alternatively, locus coeruleus involvement in the stim-
ulation field may also explain some of the findings. The Toronto
group has analyzed the effects of unilateral PPN DBS on sleep
in three PD patients and also in two patients with PSP who also
underwent PPN DBS (60). Unilateral stimulation was associated
with increased nocturnal REM sleep. This improvement occurred
without regard to the frequency of PPN DBS, which was lower in
PSP patients (5 and 30 Hz) compared to PD patients (70 Hz). REM
sleep behavior disorder, present in two patients prior to DBS, was
not modified by PPN stimulation. The results preliminarily sug-
gest that PPN DBS promotes REM sleep by increasing output from
the PPN (REM on) and by transsynaptically inhibiting the nuclei
receiving GABAergic afferents in the ventrolateral periaqueductal
gray and lateral pontine tegmentum (REM off) (79). These effects
were observed in a small group of PSP patients, and we therefore
cannot assume that these effects occur in PD. More recently, two
PD patients in the Toronto cohort had improvement in alertness
with bilateral LFS PPN DBS (10–25 Hz), whereas higher frequen-
cies (80 Hz) induced non-REM sleep in one of the patients (80).
The potential beneficial effects of PPN DBS on sleep and attention
will require further investigation.
Experimental data from animals lend support to the notion
that there is a role of PPN in cognition. Indeed, bilateral lesions
of the PPN region impact attention, executive abilities, working
memory and learning (35). Very little data are available in humans.
Working memory tasks were studied in five PD patients with bilat-
eral PPN and STN DBS implanted for at least 3 months and they
were compared to a group of non-surgical PD patients, and also
to another group of healthy subjects (81). No data were available
prior to surgery. Although three surgical patients scored below the
normal range on the neuropsychological battery, bilateral PPN
stimulation at low frequency reduced PD patients’ response times
on both the verbal and the visual-object tasks in when compared
to the condition without stimulation. These results might support
the hypothesis that PPN DBS facilitates the speeded processing
of information in the context of working memory, and this may
possibly occur by improving attention (81). It is also possible that
that this result may have been mediated by activation of ascending
cholinergic neurons to the intralaminar thalamic nuclei result-
ing in cortical activation. Indeed, some FDG and H2O15 PET
studies with PPN DBS have demonstrated increased prefrontal
cortical activation. More recently, data coming from Oxford in 11
PD patients with bilateral PPN DBS and 1 patient with unilat-
eral PPN DBS revealed an improvement in the speed of reaction
with LFS (20–35 Hz) (21). However, the authors suggested that
this improved reaction time was related to an improved motor
performance, rather than to augmentation of attention. Further
investigation is needed to determine whether enhancement of
attentional mechanisms may actually underlie the improvement
in gait observed with PPN DBS.
In summary, it is unclear what underpins improvements in
non-motor functions with PPN DBS. However, since there is some
evidence that STN and GPi DBS might have a negative impact on
some cognitive aspects in PD (3–5), PPN DBS could possibly be
a safer target in the cognitive domain, but there is limited data to
draw this conclusion.
PATIENT SELECTION
Although we have pharmacologic therapies for levodopa-
responsive symptoms, and GPi and STN DBS that effectively treat
many patients with motor fluctuations, our current surgical ther-
apies produce minimal benefits beyond the best ON-medication
state, and do not address axial PD symptoms. As noted above,
levodopa-refractory freezing and postural instability with falls
remain an important and unaddressed source of morbidity and
mortality and this is a place where PPN DBS, if shown effective,
could fill an important vacuum in the field.
There have been important lessons learned in the past decade
about the importance of carefully choosing the right candidate for
PD (non-PPN) DBS, and most expert teams now use strict crite-
ria, an interdisciplinary review, and teams carefully choose specific
and relevant outcome variables. In general, patients who are cho-
sen for STN and GPi DBS have a good response to levodopa for
the target symptoms (with the exception of medication refractory
motor fluctuations and dyskinesias), and the best candidates have
little cognitive impairment.
Response to levodopa is predictive of the response to STN and
GPi DBS. The predictive factors for response to PPN DBS are
unknown, and must be carefully defined in future studies. Unfor-
tunately, many of the published studies have small numbers of
patients (see Table 1) and have not clearly defined inclusion or
exclusion criteria. Most have been open-label, non-randomized,
and have not utilized a battery of standardized outcome measures.
Finally, it has not been clear that these studies have focused efforts
on a therapy for ON medication axial dysfunction.
DESIGNING THE STUDIES NEEDED TO MOVE THE FIELD
FORWARD
Future studies must address these problems in study design in
order to best determine the indications for and usefulness of PPN
DBS. First, inclusion criteria must strictly define and assess for the
presence of levodopa-refractory postural instability and FOG. Ide-
ally, patients should be studied at the peak effect of a suprathresh-
old dose of levodopa. In general, these problems should persist
even when the patient has peak dose dyskinesias. The methods for
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assessing postural instability and gait problems should be stan-
dardized, sensitive, and specific. Although the UPDRS is useful, it
includes few measures of postural instability and gait and so does
not describe many of complex features of these problems which
would be more effectively measured with a combination of clin-
ical rating scales and biomechanical measures. For example, the
Tinetti Performance Oriented Mobility Assessment, a falls diary,
FOG questionnaire, and walking speed might be used in combi-
nation with objective biomechanical measures of lower extremity
function and center of mass oscillations to assess dynamic pos-
tural control when standing and during locomotion. All of the
pre-operative measures should be completed post-operatively at
selected time points ON and OFF stimulation and also assessed
with and without the combined effects of anti-Parkinson medica-
tion. All measures should be performed in a double-blind fashion
and given the uncertainty about the true benefit of PPN DBS, ran-
domization of patients to immediate versus delayed surgery would
allow for a more rigorous evaluation of its benefits. Long-term
follow-up may be needed to assess the time course of improvement
of PPN DBS.
As discussed above, the relative benefits of unilateral versus
bilateral PPN DBS are unknown and it is possible that the addi-
tional benefit of bilateral stimulation is exceeded by the risk of
implanting a second electrode. Alternatively, we might find that, as
in STN and GPi DBS, there are significant additional and perhaps
synergistic motor effects. Comparing the effects of unilateral and
bilateral stimulation in patients who have already undergone bilat-
eral PPN electrode implantation could potentially provide answers
to these questions.
There is a fairly large population of patients who have previ-
ously undergone STN or GPi DBS, and now are presenting with
late development of levodopa and stimulation resistant postural
instability and gait problems. It is quite likely that they will respond
differently to PPN DBS than patients who are DBS naïve. As a
result, patients who present primarily with levodopa-refractory
postural instability and gait problems without prior DBS may need
to be studied in a separate cohort from with those with prior DBS.
The potential for development of late complications in combina-
tion with the expected progression of the underlying disease in
these patients will require that patients be tracked over several
years (likely 5–10 years) to assess for the durability of the response
to PPN DBS.
CONCLUSION
The PPN DBS field needs a large trial that is adequately powered
to detect a meaningful treatment effect. It is unlikely that the field
will be able to adequately determine the effectiveness through the
use of small pilot studies. It may be necessary to undertake a well-
designed medium sized study to evaluate the variability in response
to some of the primary outcome measures suggested above in
order to allow sample size calculation for a large multicenter
trial.
As discussed above, a number of additional investigations
should be an integral part of any large clinical trial of PPN DBS.
Correlating electrode position to clinical effects on motor and
non-motor effects of surgery and stimulation will be extremely
important to allow further refinement of the procedure, especially
with the future advent of new electrode designs and closed loop
systems incorporating responsive stimulation. Investigations to
better determine the mechanism by which PPN DBS works will
also be important in refining the technique. Based on the animal
data, PPN DBS likely increases rather than inhibits PPN out-
put and may reduce aberrant neuronal synchrony. The effects of
stimulation on cognition, mood (apathy, depression, and anxi-
ety), behavior (including impulse control disorders and DDS),
autonomic function (urinary function, bowel control and the
cardiovascular system), and sleep all should be concomitantly
examined. Adverse effects should be scrupulously gathered as part
of a large scale trial. Quality of life over the short and long term
should be carefully assessed to determine the overall impact of
the procedure on the patient’s life. Finally, one could imagine that
FOG may possibly be approached by a closed loop approach using
PPN DBS.
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